Increased odds ratio for COVID-19 in patients with recurrent aphthous stomatitis
- PMID: 33064856
- DOI: 10.1111/jop.13114
Increased odds ratio for COVID-19 in patients with recurrent aphthous stomatitis
Abstract
The ACE2 receptor, the binding sites for the COVID-19, is expressed abundantly in the oral cavity, raising the question of whether the mouth is a target for the virus in addition to organs such as kidneys and lungs. Recently, a flurry of individual case reports on oral manifestation of COVID-19 including ulceration, blistering lesions, and stomatitis were published. However, it is not clear whether the oral presentations that are not unique to the virus are indeed related to the virus and appear at a higher prevalence than in the general population. We used the i2b2 platform of hospital patient's registry to determine the odds ratio for COVID-19 in patients that were diagnosed with recurrent aphthous stomatitis, an entity restricted to the oral cavity. The overall odds ratio for COVID-19 in patients with recurrent aphthous stomatitis before adjustments was 14 and after adjustment for gender, race, and age was 13.9, 6.5, and 2.93, respectively. The odds ratio remained increased after adjustments of the comorbidities such as respiratory disease, endocrine disease, obesity, diabetes, circulatory disease, and smoking and was 3.66, 7.46, 4.6, 10.54, 7.37, and 7.52, respectively. When adjusted for recurrent aphthous stomatitis, the respiratory disease had an odd ratio of 8.56 to be associated with COVID-19. African American race and age-group 18-34 were additional significant risk factors. The present study has demonstrated a significant association between COVID-19 and RAS; however, additional longitudinal and laboratory studies are necessary to establish a cause and effect relationship between these 2 conditions.
Keywords: COVID 19; aphthous stomatitis; stomatitis.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
The association between minor recurrent aphthous stomatitis (RAS), children's poor oral condition, and underlying negative psychosocial habits and attitudes towards oral hygiene.BMC Pediatr. 2018 Apr 13;18(1):136. doi: 10.1186/s12887-018-1094-y. BMC Pediatr. 2018. PMID: 29653566 Free PMC article.
-
Comorbidity profiles among patients with recurrent aphthous stomatitis: A case-control study.J Formos Med Assoc. 2019 Mar;118(3):664-670. doi: 10.1016/j.jfma.2018.10.002. Epub 2018 Oct 19. J Formos Med Assoc. 2019. PMID: 30348492
-
Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders.Semin Cutan Med Surg. 1997 Dec;16(4):278-83. doi: 10.1016/s1085-5629(97)80017-x. Semin Cutan Med Surg. 1997. PMID: 9421219 Review.
-
Lifetime prevalence of recurrent aphthous stomatitis and its related factors in Northern Iranian population: The PERSIAN Guilan Cohort Study.Clin Oral Investig. 2021 Feb;25(2):711-718. doi: 10.1007/s00784-020-03611-y. Epub 2020 Oct 8. Clin Oral Investig. 2021. PMID: 33030579
-
Enamel defects and aphthous stomatitis in celiac and healthy subjects: Systematic review and meta-analysis of controlled studies.J Dent. 2017 Oct;65:1-10. doi: 10.1016/j.jdent.2017.07.001. Epub 2017 Jul 5. J Dent. 2017. PMID: 28688949 Review.
Cited by
-
A reflection on COVID-19 and oral mucosal lesion: a systematic review.Front Oral Health. 2023 Dec 18;4:1322458. doi: 10.3389/froh.2023.1322458. eCollection 2023. Front Oral Health. 2023. PMID: 38169876 Free PMC article. Review.
-
Estimating the prevalence of oral manifestations in COVID-19 patients: a systematic review.Osong Public Health Res Perspect. 2023 Oct;14(5):388-417. doi: 10.24171/j.phrp.2023.0033. Epub 2023 Sep 19. Osong Public Health Res Perspect. 2023. PMID: 37920896 Free PMC article.
-
The Oral Lesion in the COVID-19 Patient: Is It True Oral Manifestation or Not?Infect Drug Resist. 2023 Jul 4;16:4357-4385. doi: 10.2147/IDR.S411615. eCollection 2023. Infect Drug Resist. 2023. PMID: 37424667 Free PMC article. Review.
-
Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities.Front Immunol. 2023 Feb 1;14:1111797. doi: 10.3389/fimmu.2023.1111797. eCollection 2023. Front Immunol. 2023. PMID: 36817433 Free PMC article.
-
Impact of comorbidity on patients with COVID-19 in India: A nationwide analysis.Front Public Health. 2023 Jan 27;10:1027312. doi: 10.3389/fpubh.2022.1027312. eCollection 2022. Front Public Health. 2023. PMID: 36777781 Free PMC article.
References
REFERENCES
-
- Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. Engl J Med. 2020;382:2372-2374.
-
- Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177-1179.
-
- Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590-592.
-
- Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.
-
- Sinadinos A, Shelswell J. Oral ulceration and blistering in patients with COVID-19. Evid Based Dent. 2020;21(2):49. https://doi.org/10.1038/s41432-020-0100-z
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
